Should medically significant genetic results be offered to research participants or their at‐risk relatives?
Australian research studies now generate genetic information on thousands of participants. Some genetic results, present in a small portion of participants (< 5%), are considered medically actionable, meaning they are associated with increased risk of adult‐onset diseases, where effective risk management, prevention or treatment exists (eg, inherited cancer or cardiac disorders).1 The National Statement on Ethical Conduct in Human Research,2 which considers genomic research at Chapter 3.3, now requires an ethically defensible plan for return (or non‐return) of genetic research results. Box 1 summarises the guidelines that are relevant to the return of genetic results to research participants.2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2016; 19: 249.
- 2. National Health and Medicine Research Council, Australian Research Council, Universities Australia. National Statement on Ethical Conduct in Human Research 2007 (updated 2018). Canberra: Commonwealth of Australia, 2018. https://www.nhmrc.gov.au/about-us/publications/national-statement-ethical-conduct-human-research-2007-updated-2018 (viewed Aug 2020).
- 3. Knoppers BM, Joly Y, Simard J, Durocher F. The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Hum Genet 2006; 14: 1170–1178.
- 4. Schwartz ML, McCormick CZ, Lazzeri AL, et al. A model for genome‐first care: returning secondary genomic findings to participants and their healthcare providers in a large research cohort. Am J Hum Genet 2018; 103: 328–337.
- 5. van Rooiji J, Arp P, Broer L, et al. Reduced penetrance of pathogenic ACMG variants in a deeply phenotyped cohort study and evaluation of ClinVar classification over time. Genet Med 2020; 22: 1812–1820.
- 6. Forrest LE, Young M‐A. Clinically significant germline mutations in cancer‐causing genes identified through research studies should be offered to research participants by genetic counselors. J Clin Oncol 2016; 34: 898–901.
- 7. Rowley SM, Mascarenhas L, Devereux L, et al. Population‐based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. Genet Med 2019; 21: 913–922.
- 8. McNeil JJ, Woods RL, Nelson MR, et al. Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci 2017; 72: 1586–1593.
- 9. Lacaze P, Ryan J, Woods R, et al. Pathogenic variants in the healthy elderly: unique ethical and practical challenges. J Med Ethics 2017; 43: 714–722.
- 10. Gareth ED, Nisha K, Yit L, et al. MRI breast screening in high‐risk women: cancer detection and survival analysis. Breast Cancer Res Treat 2014; 145: 663–672.
- 11. Domchek SM, Friebel TM, Singer CF, et al. Association of risk‐reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967–975.
- 12. Lacaze P, Sebra R, Riaz M, et al. Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. Genet Med. 2020; 22: 1883–1886.
- 13. Knoppers BM, MnH Zawati, Sénécal K. Return of genetic testing results in the era of whole‐genome sequencing. Nat Rev Genet 2015; 16: 553–559.
- 14. Allen NL, Karlson EW, Malspeis S, et al. Biobank participants’ preferences for disclosure of genetic research results: perspectives from the OurGenes, OurHealth, OurCommunity project. Mayo Clin Proc 2014; 89: 738–746.
- 15. Middleton A, Morley KI, Bragin E, et al. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. Eur. J. Hum. Genet 2016; 24: 21–29.
- 16. Hallowell N, Alsop K, Gleeson M, et al. The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study. Genet Med 2013; 15: 458–465.
- 17. Ovarian Cancer Australia. TRACEBACK research project. https://www.ovariancancer.net.au/page/148/traceback-research-project (viewed Aug 2020).
Paul Lacaze is the primary investigator and Jane Tiller is an investigator on the ASPREE genomics sub‐study. Ian Campbell is the lead investigator and Alison Trainer is an investigator on the Lifepool study. We acknowledge the contributions of the Lifepool research team, the ASPREE research team and the genetics department at Royal Melbourne Hospital.
No relevant disclosures.